Balance Sheet (Annual)
HUM / Humana, Inc. Balance Sheet shows account balances for the company at points in time. Balance Sheet data includes Assets, Current Assets, Fixed Assets, Property, Plant and Equipment (PPE), Inventory, Intangibles, Liabilities, Current Liabilities, Debt, Capital Lease Obligations, Common Stock, Retained Earnings, Treasury Stock, and Shareholders Equity.
All numbers are times 1,000 except per share units.
|Cash And Cash Equivalents At Carrying Value||1,377,000||1,306,000||1,138,000||1,935,000||2,571,000||3,877,000||4,042,000|
|Available For Sale Securities Debt Securities Current||7,743,000||8,001,000||8,090,000||7,598,000||7,267,000||7,595,000||9,557,000|
|Receivables Net Current||1,034,000||733,000||950,000||1,168,000||1,161,000||1,280,000||854,000|
|Other Assets Current||1,027,000||1,670,000||2,122,000||4,011,000||4,712,000||3,438,000||2,949,000|
|Property Plant And Equipment Net||912,000||1,098,000||1,218,000||1,419,000||1,384,000||1,505,000||1,584,000|
|Available For Sale Securities Debt Securities Noncurrent||1,710,000||1,846,000||1,710,000||1,949,000||1,843,000||2,203,000||2,745,000|
|Other Assets Noncurrent||1,165,000||1,685,000||1,774,000||1,675,000||2,502,000||2,226,000||2,166,000|
|Liabilities And Stockholders Equity|
|Liability For Claims And Claims Adjustment Expense||3,754,000||3,779,000||3,893,000||4,475,000||4,976,000||4,563,000||4,668,000|
|Accounts Payable And Accrued Liabilities Current||1,783,000||2,042,000||1,821,000||2,185,000||2,212,000||2,467,000||4,069,000|
|Other Short Term Borrowings||306,000||324,000||403,000||334,000||301,000||212,000||141,000|
|Deferred Revenue Current||213,000||230,000||206,000||361,000||364,000||280,000||378,000|
|Short Term Borrowings||-||-||-||-||299,000||300,000||150,000|
|Long Term Debt Noncurrent||1,659,000||2,611,000||2,600,000||3,825,000||3,821,000||3,792,000||4,770,000|
|Liability For Future Policy Benefits||1,663,000||1,858,000||2,207,000||2,349,000||2,151,000||2,834,000||2,923,000|
|Other Liabilities Noncurrent||267,000||288,000||289,000||291,000||235,000||263,000||237,000|
|Commitments And Contingencies||-||-||-||-||-||-||-|
|Preferred Stock Value||0||0||0||0||0||0||0|
|Common Stock Value||32,000||32,000||33,000||33,000||33,000||33,000||33,000|
|Additional Paid In Capital Common Stock||1,938,000||2,101,000||2,267,000||2,330,000||2,530,000||2,562,000||2,445,000|
|Retained Earnings Accumulated Deficit||6,825,000||7,881,000||8,942,000||9,916,000||11,017,000||11,454,000||13,670,000|
|Accumulated Other Comprehensive Income Loss Net Of Tax||303,000||386,000||158,000||223,000||58,000||-66,000||19,000|
|Treasury Stock Value||1,035,000||1,553,000||2,084,000||2,856,000||3,292,000||3,298,000||6,325,000|
|Liabilities And Stockholders Equity||17,708,000||19,979,000||20,735,000||23,466,000||24,705,000||25,396,000||27,178,000|
Peers - Hospital and Medical Service Plans (6324)
ANTM / Anthem, Inc.
ANTX / Anthem, Inc., 5.25% Equity Units due 5/1/2018
ATHTF / Anthem United, Inc.
CHCR / Comprehensive Care Corp.
CI / Cigna Corp.
CNC / Centene Corp.
7h - Asif
History and Development Himax Taiwan, its predecessor, was incorporated on June 12, 2001 as a limited liability company under the laws of the ROC. On April 26, 2005, the company established Himax Technologies Limited, an exempted company with limited liability under the Cayman Islands Companies Law, as a holding company to hold the shares of Himax Taiwan in connection with its reorganization and share exchange. On October 14, 2005, Himax Taiwan became its wholly owned subsidiary through a share exchange consummated pursuant to the ROC Business Mergers and Acquisitions Law through which the company acquired all of the issued and outstanding shares of Himax Taiwan, and the company issued ordinary shares to the shareholders of Himax Taiwan. Shareholders of Himax Taiwan received one of its ordinary shares in exchange for one Himax Taiwan common share. The share exchange was unanimously approved by shareholders of Himax Taiwan on June 10, 2005 with no dissenting shareholders and by ...
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
as of ET